Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors.

ABSTRACT: Enkephalin analogues with a 4-anilidopiperidine scaffold have been designed and synthesized to achieve therapeutic benefit for the treatment of pain due to mixed mu and delta opioid agonist activities. Ligand 16, in which a Dmt-substituted enkephalin-like structure was linked to the N-phenyl-N-piperidin-4-yl propionamide moiety, showed very high binding affinities (0.4 nM) at mu and delta receptors with an increased hydrophobicity (aLogP = 2.96). This novel lead compound was found to have very potent agonist activities in MVD (1.8 nM) and GPI (8.5 nM) assays.

SUBMITTER: Lee YS 

PROVIDER: S-EPMC2678914 | biostudies-literature | 2007 Nov

REPOSITORIES: biostudies-literature